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Dermoscopy in the era of dermato-oncology: from bed to bench side and retour 
Abstract  
Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and 
malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-
eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest 
as a bridge connecting clinical with basic molecular research in dermato-oncology. Here,  we correlate 
dermoscopy patterns of nevi and melanomas with high and low susceptibility genes and somatic mutations, 
provide an overview on the clinical and dermoscopic patterns of cutaneous melanoma subtypes, and 
highlight the role of dermoscopy in the diagnosis of skin eruptions during systemic treatments of advanced 
melanoma including targeted therapies and immunotherapies.  
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Introduction: 
 Dermoscopy is a non-invasive technique that aids to increase the diagnostic accuracy of skin lesions 
of the naked eye (1,2). The technique is now standard of diagnostic care in the setting of dermato-oncology 
and is recommended by most recent melanoma guidelines (3). However, dermoscopy is not only limited to 
clinical diagnosis. Today, represents a bridge between clinical and basic research as well as in the 
management of patients receiving systemic treatment for advanced skin cancer. 
In this article, we provide an overview on dermoscopy as a link between clinical and basic research in 
dermato-oncology, whereby we pay emphasis on melanocytic skin tumors.  
High and low susceptibility genes and dermoscopy:  
 Much research has focused on genetical alterations disposing to melanoma and cancer syndromes. 
High-penetrance alleles such as CDKN2A and CDK4, but also BAP1, POT1, ACD, TERF2IP, MITF and TERT 
(4,5) are rare but have large effects whereas moderately to low penetrant genes like MC1R are more 
common and have been related to pigmentation traits, nevus counts, immune responses, DNA repair, and 
metabolism (6).  
Skin type related dermoscopic features of nevi: 
 Number, dermoscopic-histopathologic features but also size and color of melanocytic nevi are 
strongly influenced by the pigmentary trait of a given individual. Nevi in persons with a fair skin type are 
generally large (> 5mm), slightly elevated, red to light brown dermoscopically characterized by a 
structureless red to light brown pigmentation or a network pattern with a central hypopigmentation. 
Histopathologically, they correlate with intradermal or compound nevi. In contrast, dark skinned individuals 
often exhibit small (< 5 mm), flat, dark brown junctional nevi with a dermoscopic network pattern showing 
a central hyperpigmentation (Figure 1 A-D). These differences suggest a role of pigmentary genes in 
melanocyte migration and differentiation during embryogenic nevogenesis (7,8).  
Human pigmentation genes and dermoscopic patterns of melanoma:  
 Cuellàr et al. were the first to demonstrate a direct effect of MC1R variants on the dermoscopic 
appearance of melanomas (9). In their pivotal study including 9 patients with a CDKN2A mutation (3 non-
carriers of the red hair MC1R polymorphism, 3 patients with one red hair MC1R polymorphism and 3 
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patients with two red hair MC1R polymorphisms) they found that the ABCD total dermoscopy score (ie., an 
algorithm scoring different melanoma-specific criteria; TDS) for melanomas was significantly higher in non-
carriers of red hair MC1R polymorphisms than in carriers of two MC1R gene red hair variants. Moreover 
they highlighted the role of digital follow up in the management of these patients (Figure 2).Subsequent 
studies largely confirmed this preliminary observation (9-16).  Fargnoli et al. investigated the TDS scores 
in 64 melanomas of 62 patients and also concluded that melanomas of MC1R red hair polymorphism (R) 
carriers show a significant lower TDS value, mainly due to reduced dermoscopic structures such as atypical 
pigment network and color variegations compared to non-carriers of MC1R R (12).  
 Quint et al. extended the knowledge on the association of red hair color (RHC) variants in the MC1R 
on both, nevi and melanomas (14). Their analysis of 876 atypical nevi and 21 melanomas revealed that 
pigment network, dark-brown color and streaks were more frequently observed in nevi from individuals 
without RHC variants, while structureless areas were more often observed in individuals with two RHC 
variants. (14).  In another study investigating the dermoscopic features of 62 nevi in 27 patients with 
multiple melanomas, vessels were more frequently seen among CDKN2A G101W mutation carriers, while 
atypia was associated with any MC1R variant (13). In line with these findings, also Zalaudek et al. reported 
the association of RHC variants with the development of two primary “red” (amelanotic) melanomas and 
“white” (hypopigmented) dysplastic nevi (16).  
Germline mutations and morphology:  
 
 De Giorgi et al. analyzed the dermoscopic images in 12 patients with multiple primary melanomas 
and reported in about 77% of cases on an unspecific dermoscopic pattern (17). Moreover, all patients with 
a CDKN2A germline mutation in this study developed multiple primary melanomas with a striking similar 
dermoscopic and histopathologic appearance (17).  
 More recently, Orlow et al. linked MC1R and 85 other candidate loci in a cohort of 353 children 
with nevus count and dermoscopic appearance of nevi (10). In this study, IRF4 rs12203952 polymorphism 
was very strongly associated with nevus count, while the rs12203952 T allele was associated with increased 
flat nevus count and decreased counts of raised nevi. Moreover, SNPs in IRF4 and TERT were significantly 
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associated with a globular pattern, while SNPs in CDKN1B, MTAP and PARP1 showed significant 
associations with reticular-patterned nevi compared with homogeneous-patterned nevi. No association has 
however been found regarding the dermoscopic nevus pattern and nevus count and MC1R RH variants.  
 In another study evaluating the phenotypic characteristics of168 patients with melanoma and 126 
unaffected individuals, the authors reported a higher nevus count of predominant reticular dermoscopic 
nevus pattern among five of six individuals, who were carriers of the rare MITF E318K germline mutation 
(18). Remarkably, a high incidence of amelanotic melanomas was found within the group, which suggests a 
genetic interaction between the MITF E318K allele and an MC1R homozygous red hair color (RHC) variant 
genotype.  
 A similar findings has been recently reported by Potrony et al. (19), who found MITF E318K being 
significantly associated with an increased melanoma risk, development of more than one melanoma and 
high nevus count (>200 nevi). Of note, they observed two fast-growing melanomas among 2 MITF p.E318K 
carriers during dermatologic digital follow-up.  
 Wiesner et al. described for the first time two families with inactivating germline mutations of the 
BAP1 gene characterized by multiple skin-colored, elevated melanocytic tumors (20). These melanocytic 
neoplasms, nowadays also commonly referred to as “Bapomas”, revealed histopathologically epithelioid to 
atypical features with overlapping features with melanoma. Although up to date dermoscopic features 
have been described in these neoplasms, it is our experience that they exhibit structureless red to pink 
areas eventually associated with atypical vessels. Some affected patients also developed uveal or 
cutaneous melanomas. These findings were subsequently confirmed by an increasing number of 
publications and suggest that loss of BAP1 is associated with a clinically and morphologically distinct type of 
melanocytic neoplasms including uveal melanoma (20). 
Somatic mutations and dermoscopy of nevi: 
 There is mounting evidence that the epidemiology, morphology and growth dynamics of nevi and 
melanomas correlate with different types of somatic mutations (21-24) (Figure 3). In the realm of 
melanocytic nevi, it has been shown that intermediate to large congenital melanocytic nevi more 
frequently harbor mutations in the NRAS gene compared to small congenital and acquired nevi, 
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dermoscopically characterized by a globular or structureless brown pattern, which most commonly reveal 
mutations in BRAF V600E (25-29).  
 The fact that the latter both entities share the same mutation is interesting in the context that both 
also reveal overlapping features upon histopathology and dermoscopy, which do not allow a reliable 
differentiation between them in the absence of an according history (22,30). The overlapping 
morphological and genetic characteristics along with an uncertain risk of malignant transformation of both, 
small congenital and acquired nevi, therefore questions the usefulness of their current classification into 
two different subclasses (22). 
 Besides small and acquired nevi, recent studies showed a high frequency of BRAF V600E mutations 
also in actively growing compound nevi, which are dermoscopically typified by a peripheral rim of brown 
globules (21). Based on digital dermoscopic follow up studies, it has been shown that these nevi enlarge 
over time until the final disappearance of globules indicates stabilization of growth (21). At this stage, nevi 
mostly exhibit a uniform or mixed reticular pattern with the latter showing either central globules or 
structureless areas (21). Remarkably, while growing nevi harbor BRAF V600E mutations at high frequency, 
the frequency of the mutation in stable nevi decreases (21). This observation along with data from basic 
research suggesting polyclonality for BRAF mutation in nevi (31), has led to the hypothesis that BRAF 
initially drives melanocyte proliferation (21). However after limited cell cycle rounds, cells will enter 
oncogene-driven senescence (21-24).  
 Conversely, atypical Spitz tumors and blue nevi have been linked with mutations in HRAS and 
GNAQ, respectively (29,32), whereby one study reported on GNAQ mutations in about 83% of blue nevi 
(33) (Figure 3 C-D). Moreover, GNAQ seems involved also in initiation of ocular melanoma and with dark-
pigmented dermal melanoma (33).  
Somatic mutations and dermoscopy of melanoma: 
 Recently, it has been shown that melanomas with BRAF V600E or NRAS mutations reveal 
dermoscopic signs of regression (peppering) at higher frequency compared to melanoma, which are 
wildtype (wt) for the mutations (34). The authors concluded that this finding might point toward a possible 
immune behavior in BRAF/NRAS mutated melanomas.  
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 Tschandl et al. investigated the frequency of BRAF mutations in nevus associated melanomas and 
uninvolved nevi of the same patient and detected BRAF V600E mutations in 63.0% of melanomas, 65.2% of 
associated nevi and 50.0% of control nevi (35). The authors concluded that these findings do not support 
the traditional model of stepwise tumor progression, with BRAF V600E representing an initial driver event 
in melanoma progression. The same group investigated also the impact of oncogenic BRAF V600E 
mutations and p16 expression on the growth rate of early melanomas and nevi in vivo (36). Expression of 
BRAFV 600E and the loss of p16 were associated with an accelerated growth rate of early melanomas in 
digital dermoscopic monitoring but not in melanocytic nevi.  
 Instead, melanomas with a dermoscopically dark homogeneous streak pattern have been recently 
linked to a specific KIT mutation (37). This finding is consistent with a previous report showing that KIT was 
mutated/overexpressed in darkly pigmented cutaneous melanomas (38).  
Integrating clinical and molecular findings into melanoma classification:  
 It must be acknowledged that term melanoma refers to a heterogeneous group of melanocytic 
proliferations that differ significantly with respect to their morphology, epidemiology, growth rate and 
capacity metastasize. Currently, different schemes are applied depending on the employed method to 
obtain information. As such melanomas can be classified based on morphological criteria (clinical-
dermoscopic-histopathological), growth rate (slow and fast growing), sites of origin (chronic, intermittent, 
no UV-exposure) and genetical alterations (39-42). Using a combined classification approach that integrates 
clinical morphology with epidemiology and genetics, the following melanoma subtypes can be 
distinguished (Figure 4). 
Slow growing melanoma:  
 There is mounting evidence for the existence of a group of melanomas characterized by a slow in 
situ growth over a long period of time and low metastatic potential (43-45). This subtype can be considered 
equivalent to lentiginous or superficial spreading melanoma and has been associated with a strong increase 
in incidence, development on intermittent sun-exposed areas, a high nevus count, and mutations in the 
BRAF V600E gene (46).  
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 Clinically this melanoma frequently exhibits the 3 or more criteria of the ABCDE rule such as 
asymmetry, border irregularity, color variegations, diameter more than 6 mm and evolution over time.  
 Dermoscopically, it is characterized by a network pattern and areas of regression (characterized by 
white structureless areas and gray dots). Direct proof for the existence of such slow growing melanoma is 
achieved by digital dermoscopic monitoring studies showing only subtle changes during a mean follow up 
of 20 months (44,45). (Fig.5) 
Fast growing melanoma: 
 Fast growing melanoma can be regarded equivalent to nodular melanoma, which is a rapidly 
progressing and potentially lethal skin tumor (47). Some question whether nodular or fast growing 
melanoma arises from the epidermis or develops initially in the dermis (48) (Figure 6). It shows a relatively 
stable incidence and is neither associated with a specific sun-exposure pattern, high nevus count nor with 
specific mutations, although NRAS mutations appear more commonly in this subtype than in others (49).  
 The EFG (elevation, firm on palpation and continuous growth for more than 1 month) rule has been 
proposed for its clinical diagnosis (50). Fast growing melanoma can be heavily pigmented or amelanotic.  
 The blue and black rule is an easy dermoscopic clue to diagnose fast growing pigmented/ nodular 
melanoma and refers to the contemporary presence of structureless blue areas intermingled with black 
dots/globules/blotches or bizarre structures (51,52). Of note, the histopathological correlates of black 
structures are either hemoglobin or melanin in the upper epidermis, whereby this can be due to ulceration, 
pigmented parakeratosis, pagetoid spread of melanocytes or to large nests of heavily pigmented melanoma 
cells just beneath a very thinned epidermis, respectively. Especially the latter feature has been discussed as 
predictive feature for developing ulceration before it becomes clinically manifest (52,53). Further patterns 
that occur at variable frequency are asymmetric pigmentation, disorganized polychromatic patterns, 
grey/blue structures, white short lines using cross polarized light, peripheral black dots/globules, large-
diameter vessels and milky red areas (47,54-57). 
 In contrast, amelanotic fast growing melanoma reveals atypical vascular structures like 
polymorphous vessels (dotted and linear), milky-red globules/areas and homogeneous red/pink areas 
(58,59).  
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Lentigo maligna melanoma: 
 Lentigo maligna (LM) belongs to a group of very slow growing melanomas and may remain in this in 
situ phase for years, if not decades (60). LM shows a slight increased incidence over the past decades and is 
strongly associated with chronic sun-exposure, but not with a high nevus count or mutations in BRAF or 
NRAS or KIT.  
 The diagnosis of LM remains challenging even if coupled with dermoscopy, because most criteria 
overlap also with other pigmented facial macules such as pigmented actinic keratosis or solar lentigo 
(48,61-66). However, it has been shown that grey color is the single most important dermoscopic criterion 
for diagnosing lentigo maligna melanoma. (67,68) (Figure 7). 
Acral-lentiginous melanoma:  
 Acral lentiginous melanoma can be regarded a melanoma subtype of likely intermediate growth 
that arises from the glabrous skin of the soles and palms or from the nail matrix (i.e., subungual 
melanoma). It has a stable incidence but no association with sun-exposure or with a high nevus count. 
Mutations, if present, involve KIT or cyclin D1 (41,69).  
Acral melanoma: 
 
 Acral melanoma arising from the glabrous skin presents typically as large, inhomogeneous-
pigmented macule or plaque measuring more than 7 mm (70). Dermoscopically, early acral melanoma 
exhibits a parallel-ridge pattern, composed by broad parallel pigmentation lines that are seen in 
correspondence to the ridges of the glabrous skin (Figure 8 A-B). This pattern achieves a very high 
specificity and sensitivity (99% and 86.4%, respectively) for the diagnosis (71). Very recently, a scoring 
system (named BRAAFF) composed of six variables was proposed for the diagnosis of AM. This method 
includes four positive (irregular blotches, ridge pattern, asymmetry of structures and asymmetry of colors) 
and two negative predictors (furrow pattern and fibrillar pattern) (72).  
 Of particular interest is the study by Yamaura et al., who investigated the dermoscopic patterns 
and amplifications in the cyclin D1 gene in 16 histopathologically equivocal, acral melanocytic skin lesions 
(73). Nine of these 16 lesions exhibited the parallel ridge pattern by dermoscopy suggestive for melanoma 
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in situ, and 4 (44%) of them had also amplifications of the cyclin D1 gene. Amplifications were not found in 
any of the remaining 7 lesions that showed dermoscopic patterns suggestive of a benign melanocytic nevus 
(fibrillar, parallel furrow or lattice like pattern).  
 Based on these finding, the authors concluded that cyclin D1 gene amplification and a dermoscopic 
parallel ridge pattern can be identified in a very early progression phase of acral melanoma that precedes 
histopathologically defined melanoma in situ.  
Subungual melanoma: 
 The so-called ABCDEFG rule has been proposed to memorize the most salient clinical and 
epidemiological data of this melanoma subtype (74). In this system, A refers to either to age (peak 
incidence after 5th decade of life) or African Americans, Asians, and native Americans. B stands for brown to 
black band-like pigmentation with a breadth of 3 mm or more. C stands for change in the nail plate while D 
stands for the first digit most commonly involved; E stands for extension of the pigment onto the proximal 
and/or lateral nailfold (ie, Hutchinson's sign); and F stands for family or personal history of dysplastic nevus 
or melanoma.  
 Dermoscopically, early subungual melanoma reveals a band like pigmentation composed by lines of 
different width and color (75) (Figure 8 C-D).  
Mucosal melanoma:  
 Similar to acral lentiginous melanoma, also mucosal melanoma lacks association with UV-expose or 
multiple nevi and harbors most commonly KIT mutations (41).  Dermoscopically, this melanoma subtype 
commonly reveals a combination of blue, gray or white color (76), whereby the frequency of dermoscopic 
patterns is influenced by the tumor thickness (77,78).  
 A study including melanomas of the oral and genital mucosa and semi-mucosa revealed that 75% of 
these lesions presented with a multi-component pattern and only 25% with a homogeneous pattern in 
dermoscopy (79,80).  
Dermoscopy of secondary skin neoplasms related to the systemic treatment of advanced melanoma 
Alterations in melanocytic lesions under targeted therapy:  
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 Among a number of cutaneous side-effects during Braf-Inhibitor treatment (BRAFi) with 
vemurafenib are alterations of the melanocyte and keratinocyte system (Figure 9 A-D). These include 
growth and involution of new and pre-existing nevi, respectively as well as the development of new 
melanomas either de novo or within pre-existing nevi (81,82).  
 Up to date, newly evolving nevi under BRAFi therapy were shown to be wildtype with regard to the 
mutation, while stable or involuting nevi harbor the mutation (83).  
 In line with a study correlating the dermoscopic features of nevi with BRAF mutations (84), 
involuting nevi under vemurafenib treatment typically reveal a globular and/or structureless brown pattern 
upon dermoscopy, while conversely, newly developing BRAFwt nevi are characterized by a reticular pattern 
(85) (Figure 9 A).  
 Interestingly, Dalle S et al. were the first reporting on the development of melanomas in patients 
receiving vemurafenib for metastatic melanoma (86). In detail, they reported on 6 early BRAFwt primary 
melanomas evolving from 6 atypical melanocytic lesions in 4 patients 4 to 12 weeks after initiation of 
vemurafenib therapy (87) (Figure 9B).  
Subsequent publications confirmed the development of second primary melanomas either de novo or from 
pre-existing lesions under BRAFi therapy, which are all wt for the mutation (81,88-94). 
  However, there are two aspects with regard to these findings that should receive special attention: 
First, nevi initially lacking atypia have been shown to develop striking atypia under BRAFi therapy (92). 
Second, the reported incidence of second primary melanomas in patients receiving vemurafenib is 
unexpected higher (21%) compared to the general population (estimated 5%) (88).  
 Although it might be possible that these second primary melanomas could present initially 
dormant, but due BRAFi paradoxically activated melanomas, another plausible explanation has been 
postulated by another group (94), who question whether these melanomas should be rather regarded 
drug-activated nevi showing marked atypia as it is also reported in other activated nevi such as after UV-
exposure, epidermolysis bullosa nevi or recurrent nevi.   
Squamous cell carcinoma under BRAFi therapy 
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 The development of cutaneous squamous cell carcinomas and keratoacanthomas was reported 
under vemurafenib and to much lesser extend under dabrafenib therapy (93,95). These tumors are 
characterized by white circles, white structureless areas, hairpin vessels or coiled vessels, scales and central 
masses of keratin appearing as yellow to white structureless areas with splitter hemorrhages (Figure 9 C).  
Inflammatory skin reactions under BRAFi therapy 
 Another commonly observed adverse effects affecting the skin under vemurafenib therapy is 
acantholytic dyskeratosis (96,97). Also for this condition, specific dermoscopic patterns have been 
described, which consists of a yellow opaque star-like center with a white outline overlying a red to brown 
area (Figure 9D) (98-100).  
Cutaneous eruptions under check point blockade therapy  
 Among series of reported cutaneous side effects under immunotherapy using CTLA-4 antibodies, 
PD-1 inhibitors and PDL-1 inhibitors are lichenoid eruptions (101).  
 Dermoscopy for their diagnosis is of particular value as dermoscopic patterns of lichen planus are 
highly specific and consist of white crossing lines (corresponding to the histopathological correlate of the 
Wickham striae) over a typically reddish to violaceous background with some dotted vessels (102).The 
specific features originally described for lichen ruber planus, allowing also a reliable diagnosis of lichenoid 
eruptions in patients receiving immunotherapy for metastatic melanoma (Figure 10 A-D).  
Expert commentary 
 Dermoscopy is a widely accessible, fast and non-invasive diagnostic method that improves the 
clinicians’ ability to diagnose skin cancer at an earlier stage compared to the unaided eye. The use of digital 
dermoscopic monitoring has allowed for the identification of specific dermoscopic patterns predictive for 
the growth of both, nevi and melanoma. The increasing knowledge that specific molecular alterations 
correlate with specific clinical morphologies is of interest for clinical and basic research but also for the 
practical management of patients.  
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Five-year view 
 Dermoscopy, but also more recent non-invasive skin imaging tools such as confocal microscopy, or 
optical coherence tomography will increasingly improve the understanding of melanocytic morphology and 
biology. Currently there is much research ongoing focusing on the identification of biomarkers predictive 
for response to treatment. Whether or not specific morphological patterns may become useful as 
biomarkers in the future remains at current an open question. However, first studies in this field suggesting 
specific morphological patterns associated with specific molecular alterations point towards such 
possibility. A further very intriguing era of research will be the in vivo observation of changes during 
treatment, which might further open new insights into the developmental steps of melanocytic skin tumors 
and the interaction between the melanocyte and keratinocyte system. Overall, it can be however 
previewed that dermoscopy will not be replaced in the next 5 years as routine tool for skin cancer 
screening, but new methods might be considered important adds on to improve the knowledge about 
growth rate and response to treatment.  
 
Key issues  
- Dermoscopy is a standard technique that improves the clinicians’ accuracy to diagnose and manage 
skin tumors compared to the naked-eye examination. 
- Dermoscopy is integrative part of the management in dermato-oncology 
- Genetical alterations correlate well with morphology or specific topographies of melanocytic skin 
tumors 
- Nevi as well as melanomas in carries of the red hair polymorphism of the MC1R gene often reveal 
structureless light brown to red color 
- BRAF V600E is the most common mutation in nevi and melanoma. In both, the presence of the 
mutation is correlated to specific dermoscopic features 
- The classification of melanoma is an evolving science and correlates morphological aspects of 
melanoma with biological behavior and molecular alterations 
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- Dermoscopy aids the diagnosis and management of dermatological adverse effects during novel 
targeted and immune therapies.   
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Figure legends:  
 
Figure 1: Skintype related nevus patterns: Nevus patterns of persons with a fair skin type (A,B); Nevus 
pattern of a person with a skin type 3 (C) and 4 (D) according to Fitzpatrick 
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Figure 2: Dermoscopic features of nevi (indicated as N) and melanomas (indicated as MM) excised during a 
6 years surveillance program of a male patient with a CDKN2A mutation. Of note, a significant proportion of 
melanomas have been exclusively detected during digital dermoscopic follow up (indicated as MM-FUP) 
revealing suspicious, clinically not visible, changes over time. 
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Figure 3: Correlation of reported somatic mutations and clinical-dermoscopic morphology of nevi. (A) 
Intermediate sized congenital nevus have been associated with mutations in the NRAS gene; (B) Acquired 
growing compound nevus characterized by small peripheral globules as sign of growth. This nevus revealed 
a mutation in BRAF V600E; (C) Atypical Spitz nevi have been linked to HRAS mutations. (D) Blue nevi have 
been linked  to mutations in GNAQ.  
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Figure 4: Somatic mutations in melanoma in relation to a specific morphology and topography. (A) BRAF 
V600E mutated melanoma often reveal signs of regression composed by white and blue-gray structures. (B) 
Uveal melanoma or malignant blue nevus harbor frequently mutations in GNAQ. (C) Acral and mucosal 
melanoma often harbor KIT mutations. (D) MITF p.E318K mutations have been associated with an 
amelanotic phenotype, dermoscopically characterized by atypical vessels.  
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Figure 5: Stereotypical clinical, dermoscopic and histopathological features of slow growing melanoma 
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Figure 6: Stereotypical clinical, dermoscopic and histopathological features of pigmented, fast growing 
melanoma 
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Figure 7: Stereotypical clinical, dermoscopic and histopathological features of lentigo maligna and lentigo 
maligna melanoma 
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Figure 8: Stereotypical clinical, and dermoscopic patterns of acral (A,B) and subungual (C,D) lentiginous 
melanoma 
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Figure 9: Clinical overview and close up of dermoscopic patterns of cutaneous side effects during treatment 
with vemurafenib. (A) eruptive nevi commonly show a network pattern and are wt for the BRAF mutations; 
(B) atypical melanocytic tumor characterized by an inverse network (white small lines forming a network) 
pattern and growth during treatment; (C) typical feature of a squamous cell carcinoma – keratoacanthoma 
type; (D) stereotypical appearance of acantholytic dyskeratoma  
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Figure 10: Clinical (A) and dermoscopic features (inserts) of lichenoid reaction observed during treatment 
with a PD-1 antibody.  
 
 
 
D
ow
nl
oa
de
d 
by
 [E
mo
ry
 U
niv
ers
ity
] a
t 0
3:4
5 2
4 M
arc
h 2
01
6 
